L. Looijenga

Prof. dr., Groupleader, Managing Director Research, Medical Cell Biologist, Medical Cell Biologist

  • Heidelberglaan 25

    3584 CS Utrecht

    Nederland

1990 …2022

Onderzoeksresultaten per jaar

Als u wijzigingen in Pure hebt gemaakt, zullen deze hier binnenkort zichtbaar zijn.

Persoonlijk profiel

Personal profile

Short biography: Leendert Looijenga is Medical Cell Biologist by training (Cum Laude, 1989) and Professor of Translational Patho-Oncology (since 2005, endowed since 2017). He received his PhD in Medical Biology from Erasmus University (Rotterdam) in 1994. Since 1990 he is leading a research group studying translational aspects of Germ Cell Tumors (GCTs), focusing on understanding the pathogenesis and clinical behavior, with the aim to develop informative diagnostic, prognostic and predictive biomarkers. In 2018 he started his activities at the Princess Máxima Center for Pediatric Oncology focusing on pediatric and adolescent and young adult GCT patients, with the mission to improve diagnosis and treatment response, resulting in optimal long-term quality of life. Looijenga has been involved in the testicular GCT patient support group (zaadbalkanker) since its origin in 1996. He received project grants from KWF, NWO/ZonMW (including VIDI) and Industry, accounting for 16 during the last 5 years (57 in total). Leendert Looijenga published multiple papers and book chapters. These include papers in (Cancer) Cell, Nature Reviews, Cell Reports, Genome Biology, European Urology and the Journal of Clinical Oncology. His H-index (August 2022) is 108, with 48,903 citations (26,276 since 2017). Looijenga filed two patents in the last 3 years. Looijenga his field-weighted citation impact in the last 5 years is 7.18. Over 52% of his outputs over that period are in the 10% citation percentile and over 60% of his publication outputs are in the top 10% Journal percentiles (77% top 25%). Over 68% of his primary papers include international collaborations. Looijenga gave 75 invited seminars in the last 5 years. Looijenga his first publication related to platin-resistance of GCTs was in 1999, followed by 15 since then. The major most recent related breakthrough is the 2022 Journal of Clinical Oncology paper.

Publications

Professional Information

1990: Junior Scientist Daniel den Hoed Cancer Center Rotterdam

1999: Assistent Professor Academic Hospital Rotterdam/Daniel den Hoed Cancer Center

2005: Professor Translational Patho-Oncology, Erasmus Medical Center, Rotterdam

2014: BKO (Teaching certificate)

2017: Endowed Professor Translational Patho-Oncology, Erasmus Medical Center, Rotterdam

2018: Groupleader Princess Maxima Center, Utrecht

2021: Groupleader (50%) and Managing Director (50%) Princess Maxima Center, Utrecht

 

URL

Opleiding / Academische kwalificatie

Ph.D., Erasmus University Medical Center

Datum van toekenning: 9 nov. 1994

Doctorandus, The University of Groningen

Datum van toekenning: 25 mei 1989

Externe posities

Prof. Translationele Patho-Oncologie, Erasmus MC University Medical Centre

Trefwoorden

  • Q Science (General)
  • Embryology
  • Germ cell (tumors)
  • Gonad development and function
  • (Tissue and liquid biopsy) Biomarkers
  • Treatment sensitivity and resistance
  • (in)Fertility and preservation
  • In vitro and in vivo model system
  • (Pediatric) Oncology

Vingerafdruk

Verdiep u in de onderzoeksgebieden waarop L. Looijenga actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
  • 1 Soortgelijke profielen

Netwerk

Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of